For the quarter ending 2026-03-31, RNTX had $1,230K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 3,073 | - | - | - |
| General and administrative expenses | 2,157 | - | - | - |
| Other (expense) income, net | -608 | - | - | - |
| Net loss | -5,838 | -31,967 | -5,581 | -12,323 |
| Commitment fee related to pre-paid advance agreement | - | 0 | 300 | - |
| Original issue discount related to pre-paid advance agreement | - | 50 | 100 | - |
| Depreciation and amortization expense | - | 0 | 0 | 1 |
| Stock-based compensation expense | 156 | 257 | 1,447 | 520 |
| Impairment loss on intangible assets | - | 28,700 | - | - |
| Net amortization of discount on notes payable | 623 | - | - | - |
| Prepaid expenses and other current assets | -103 | -15 | 219 | 115 |
| Other assets | 1,003 | 0 | -2,344 | 2,344 |
| Accounts payable | 2,288 | -147 | -1,905 | 5,117 |
| Operating lease liabilities | - | 0 | 0 | 0 |
| Accrued expenses and other current liabilities | 247 | 584 | -34 | -3,172 |
| Other long-term liabilities | 0 | 0 | 0 | -277 |
| Deferred tax liabilities | - | -712 | - | - |
| Net cash used in operating activities | -3,424 | -3,220 | -3,548 | -12,593 |
| Proceeds from issuance of common stock in connection with warrant exercises, net of costs | - | 0 | 0 | 1,595 |
| Proceeds from issuance of warrants, net of offering costs | - | 0 | 0 | 481 |
| Proceeds from issuance of common stock, net of offering costs | 354 | 1,452 | 0 | 367 |
| Proceeds from pre-paid advances | - | - | 1,900 | - |
| Proceeds from pre-paid advances, net of discounts | - | 2,850 | - | - |
| Proceeds from warrant exchanges, net of offering costs | - | 0 | 0 | 2,984 |
| Proceeds from issuance of common stock in connection with stock option exercises | 0 | 3 | 0 | 1 |
| Proceeds from warrant exercises with common stock subscribed | - | 0 | 0 | 22 |
| Notes payable, net | 4,300 | - | - | - |
| Net cash provided by financing activities | 4,654 | 2,405 | 1,900 | 5,450 |
| Effect of exchange rate changes on cash and cash equivalents | - | -18 | -26 | 0 |
| Net increase (decrease) in cash and cash equivalents | 1,230 | -833 | -1,674 | -7,143 |
| Cash and cash equivalents at beginning of period | 3,215 | 4,048 | 12,865 | - |
| Cash and cash equivalents at end of period | 4,445 | 3,215 | 4,048 | - |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)